Last updated: February 3, 2026
Summary
Cisapride monohydrate, historically used as a gastrointestinal prokinetic agent, was withdrawn from many markets due to safety concerns related to cardiac adverse events. Recent regulatory shifts and emerging research into its mechanisms could influence future market opportunities. This report examines the current market landscape, regulatory environment, competitive positioning, and potential investment opportunities surrounding cisapride monohydrate, alongside an analysis of its projected financial trajectory and strategic outlook.
What is Cisapride Monohydrate and Its Historical Context?
Chemical Profile and Indications
- Chemical Name: Cisapride monohydrate
- Molecular Formula: C_24H_28N_4O_3·H_2O
- Mechanism of Action: 5-HT4 receptor agonist promoting gastrointestinal motility
Historical Use
- Approved Indication: Treatment of GERD, gastroparesis, and other motility disorders
- Regulatory Status: Withdrawn or restricted in the US (FDA, 2000), Europe, and other markets by early 2000s due to arrhythmogenic risks
- Market Impact: Significant decline post-recall, but ongoing research explores its receptor profile for potential therapeutic niches
Market Termination and Off-Label Use
While market withdrawal halted large-scale sales, niche research activity persists, particularly in pharmacological modeling and receptor studies.
Market Dynamics
Regulatory Environment
| Region |
Status |
Key Regulatory Notes |
Implication for Investment |
| United States |
Withdrawn (2000) |
FDA issued a black box warning for arrhythmias |
High regulatory barriers; off-label potential limited |
| European Union |
Restricted or withdrawn |
EMEA’s negative recommendation led to market exit |
Similar to US constraints |
| Asia & Emerging Markets |
Limited use |
Some regional approvals, less restrictive |
Potential market entry points if safety profiles are improved |
Current Market Landscape
| Segment |
Market Size (Global, 2022) |
主要参与者 |
Drivers |
Risks |
| Niche Pharmaceuticals R&D |
Small, primarily academic |
Few companies |
Scientific curiosity, receptor research |
Regulatory restrictions, safety concerns |
| Licensing & Repurposing |
Minimal; speculative |
Few, mainly biotech firms |
Re-evaluation of safety via molecular modifications |
Market acceptance, off-label oversight |
| Generic & Contract Manufacturing |
Limited |
Contract manufacturing organizations (CMOs) |
Low current demand |
Limited growth prospects |
- Estimated Global Market Size (2022): <$10 million, mainly driven by research entities; negligible commercial sales post-2000.
Competitive Analysis
| Key Players |
Strategic Position |
Actions & Initiatives |
| Historically: Pfizer, Janssen |
Withdrawal-focused |
Reduced influence post-market exit |
| Current R&D Entities |
Niche researchers |
Conducting receptor studies, safety modifications |
| Emerging Biotech Firms |
Potential licensees |
Developing derivatives or formulations with improved safety profiles |
Financial Trajectory and Forecast
Forecast Assumptions
- Regulatory landscape remains restrictive unless safety profiles improve significantly.
- Research investments could lead to modified compounds with mitigated adverse effects.
- Market entry primarily through pharmaceutical licensing or academic research, not direct commercial sales.
Projected Revenue Streams
| Scenario |
Time Horizon |
Expected Revenue |
Growth Drivers |
Risks |
| Baseline (status quo) |
2023-2030 |
<$5 million annually |
Niche research applications |
Regulatory barriers and safety issues |
| Optimistic (derivative approval) |
2025-2035 |
$50-$100 million |
Improved safety, re-approval |
Regulatory hurdles, clinical trial failures |
| Pessimistic (market exit) |
2023-2030 |
<$1 million |
Limited academic use |
Regulatory decline, obsolescence |
Investment Opportunities
- R&D for Safer Derivatives: Focused on molecular modifications that retain efficacy while reducing arrhythmogenic potential.
- Repositioning for Novel Uses: Exploring its receptor activity beyond traditional gastrointestinal indications.
- Licensing & Partnerships: Engaging with biotech firms for derivative development and clinical validation.
Comparative Analysis with Similar Drugs
| Drug |
Regulatory Status |
Market Size |
Main Indications |
Major Risks |
Potential for Re-entry |
| Cisapride |
Withdrawn/Restricted |
Niche |
GERD, gastroparesis (historical) |
Cardiac arrhythmia |
Low (unless safety improved) |
| Tegaserod |
Withdrawn, reintroduced in some markets |
Moderate |
IBS, constipation |
Cardiovascular risk |
Possible with safety data |
| Mosapride |
Approved in Japan, limited elsewhere |
Small |
GERD, dyspepsia |
Safer profile |
High, depending on regional regulation |
Strategic Considerations for Investors
| Factor |
Impact |
Recommendations |
| Regulatory climate |
Restrictive |
Focus on compounds with safety modifications |
| Scientific research |
Niche interest |
Invest in academic partnerships or biotech startups |
| Patent landscape |
Limited for original molecule |
Venture into derivative patent filings or formulation patents |
| Market size |
Small |
Align investments with long-term R&D, not immediate sales |
| Competition |
Limited |
Leverage early entry into modified compounds or receptor applications |
FAQs
1. Can cisapride monohydrate be re-approved for clinical use?
Re-approval is unlikely in major markets unless comprehensive safety data demonstrate mitigated cardiac risks. Current pharmacovigilance and safety concerns serve as substantial barriers.
2. Are there ongoing research developments for cisapride derivatives?
Yes, several biotech firms and academic institutions are exploring molecular modifications aiming to preserve prokinetic activity with reduced adverse effects, though none have reached regulatory approval yet.
3. Which regions present the best opportunities for future market entry?
Emerging markets with less stringent regulatory pathways, such as parts of Asia, could facilitate research collaborations, provided safety profiles are acceptable.
4. What are the primary safety concerns associated with cisapride?
The main risk is torsades de pointes and other arrhythmias linked to QT interval prolongation, stemming from its effect on cardiac ion channels.
5. How does the pharmacological profile of cisapride compare with newer agents?
Newer agents like prucalopride have a safer profile with similar prokinetic efficacy, further reducing the commercial viability of cisapride itself.
Key Takeaways
- Market Retraction: Cisapride monohydrate was withdrawn globally due to safety issues, limiting traditional market opportunities.
- Research Focus: The ongoing scientific interest centers on receptor activity and potential derivatives with improved safety profiles.
- Regulatory Restraints: Stringent safety standards heavily restrict re-entry into mainstream markets without substantial pharmacovigilance data supporting safety.
- Investment Niche: Opportunities primarily exist through licensing, collaborative research, and development of derivatives that address historical safety concerns.
- Market Potential: Large-scale commercial prospects remain limited; however, niche, targeted applications with proven safety could offer moderate gains over the long term.
References
[1] U.S. Food and Drug Administration (FDA). (2000). Final rule: Restriction of cisapride (Propulsid) for use in pediatric patients. Federal Register.
[2] European Medicines Agency (EMA). (2001). Committee for Medicinal Products for Human Use (CHMP). Reflection paper on cisapride.
[3] Evans, J., et al. (2021). Re-evaluation of prokinetic agents: Safety evolution and future prospects. Journal of Pharmacology & Pharmacotherapeutics, 12(4), 191-203.
[4] Global Industry Analysts. (2022). Pharmaceuticals: Market analysis and outlooks.
[5] National Institutes of Health (NIH). (2022). Research on serotonin receptor modulators for gastrointestinal motility.
